Women with HIV receiving depot medroxyprogesterone acetate (DMPA), with efavirenz (EFV)-based ART and rifampicin (RIF)-based TB treatment, had lower MPA plasma levels compared with women not receiving the two drugs. 

Adjusted doses of darunavir/ritonavir (DRV/r) with rifampicin (RIF) were associated with unacceptable risk of hepatotoxicity and a reduction in DRV trough concentrations in a pharmacokinetic (PK) study, conducted in South Africa, presented at CROI 2019.
  

Dolutegravir (DTG) can be given with short-course TB preventive therapy of 12 once-weekly rifapentine/isoniazid (3HP) without dose adjustment, according to data from the DOLPHIN trial, presented at CROI 2019. [1]

Plasma concentrations of tenofovir alafenamide AUC were decreased by 55% and intracellular tenofovir-diphosphate concentrations by 36% when given with rifampicin. But intracellular concentrations were still 76% higher than those with standard dose tenofovir disoproxil fumarate.

Twice-daily tenofovir alafenamide (TAF) plus rifampicin provided similar exposures to once-daily TAF in pharmacokinetic study. This strategy might be a suitable option for people with HIV/TB coinfection.

Twice daily dolutegravir in combination with rifampicin was well tolerated and produced good outcomes in a small retrospective study presented at HIV Drug Therapy Glasgow 2016. [1]  

Generic production could make novel multidrug-resistant tuberculosis (MDR-TB) regimens available for US $53–507 per treatment course according to data presented at TB2016.

The nine-month Bangladesh regimen for treatment of multidrug-resistant tuberculosis (MDR-TB) was successful in 83% of children and adolescents in an observational trial conducted in francophone Africa, presented at TB2016. [1]

Levofloxacin was safe and well tolerated in children with and without HIV in long-term use. The data provide additional support for its inclusion in paediatric TB treatment and prevention regimens. [1]

Cotrimoxazole/isoniazid/pyridoxine (CTX/INH/B6) scored fixed dose combination (FDC) tablets are bioequivalent to individual drugs and are acceptable, reduce pill burden and could improve adherence for adults and children, according to results from the REALITY trial presented at the 46th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union).